A growing set of late-stage oncology updates highlighted shifting treatment strategies across lung and prostate cancer. In metastatic urothelial cancer, data explored combining tremelimumab and durvalumab—both immune checkpoint antibodies—with paclitaxel in a Phase I/II regimen, seeking evidence of synergy and tolerability. In bladder cancer diagnostics, 10x Genomics and Cleveland Clinic are moving toward spatial biomarker discovery aimed at predicting response to ADCs. The collaboration will use 10x Xenium, Flex Apex, and forthcoming Atera platforms to connect tumor microenvironment features with therapeutic response. Together, the items underscore how oncology development is increasingly coupling immunotherapy regimens and combination schedules with spatial and multi-omic readouts to guide next treatment selections.